Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche Rituximab shows...

    Roche Rituximab shows positive data in rare skin disease Pemphigus Vulgaris

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-15T09:00:25+05:30  |  Updated On 15 Oct 2019 9:00 AM IST
    Roche Rituximab shows positive data in rare skin disease Pemphigus Vulgaris

    New Delhi: Roche recently announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).


    PV is a rare, serious and potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. MMF is a commonly used, unapproved treatment for PV that is recommended in published treatment guidelines.

    MabThera/Rituxan became the first biologic therapy for PV when it was approved by the FDA in June 2018 and the European Commission on March 2019. These approvals were based on data from the Roche-supported Ritux 3 clinical trial. The PEMPHIX study provides additional clinical evidence of the effectiveness of MabThera/Rituxan for PV.


    The study met the primary endpoint at Week 52 and demonstrated that MabThera/Rituxan is superior to MMF, with 40.3% of patients treated with MabThera/Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm (p<0.0001).


    The phase 3 PEMPHIX study met its primary endpoint at week 52 and demonstrated that Rituxan is superior to mycophenolate mofetil (MMF), with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm.


    Read Also: Roche presents positive Phase III results for Tecentriq


    Commenting on the same, Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development said, “The approval of MabThera/Rituxan for the treatment of pemphigus Vulgaris was the first major advancement in the treatment of this rare, serious disease in more than 60 years.”


    “The PEMPHIX study showed that 40 per cent of people in the study could achieve complete remission from painful blistering without the need for corticosteroids for 16 weeks or more and that Mabthera/Rituxan may be a superior treatment option to mycophenolate mofetil, ” Levi added.


    The study is ongoing, with patients participating in a 48-week safety follow-up period after treatment completion or discontinuation.


    Read Also: Roche wins USFDA breakthrough status for Gayzva for lupus nephritis

    EADVEuropean Academy of DermatologyLevi GarrawayMabTheraMMFmofetilMycophenolateMycophenolate Mofetilpemphigus vulgarispharmapharma companypharma newsPVRituxanRituximabRochesteroidsVenereology
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok